Vaniqa, a hair growth retardant, is indicated to reduce unwanted facial hair in women. Vaniqa (eflornithine HCl; Allergan) Cream 13.9% is currently unavailable due to a shortage of active ingredient, ...

CARLSBAD, Calif.--(BUSINESS WIRE)--June 28, 2004--SkinMedica(R) Inc., a specialty pharmaceutical company developing and commercializing dermatology products, announced today that it is the winning ...

Eflornithine 13.9% (Vaniqa) cream is FDA-approved to reduce growth of unwanted facial hair in women. A randomized trial of 33 women aged 22-65 years evaluated the efficacy of eflornithine use in ...

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa ® and ...

Please provide your email address to receive an email when new articles are posted on . Cipher Pharmaceuticals announced it has acquired the Canadian commercialization rights to Vaniqa and Actikerall ...

VaniqaT is a prescription drug which was approved by the FDA in the United States on July 31, 2000 for treating excessive facial hair in women, which is often part of hirsutism. It may be a welcome ...

Please provide your email address to receive an email when new articles are posted on . Cipher Pharmaceuticals announced the Canadian market launch of Vaniqa, which was recently licensed from Almirall ...

Cipher Pharmaceuticals Inc, a rapidly growing specialty pharmaceutical dermatology company, has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa and ...